2022
Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Lockwood B, El-Jawahri A, Walker A, Ehrman S, Russell D, Kale S, Gustin J, Bose-Brill S, LeBlanc T, Luger S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Journal Of Adolescent And Young Adult Oncology 2022, 12: 592-598. PMID: 36367711, DOI: 10.1089/jayao.2022.0082.Peer-Reviewed Original ResearchConceptsYoung adultsHigh-risk AMLUnpredictable illness trajectoriesPatient-reported outcomesHospitalized young adultsHighest post-traumatic stress disorderPost-traumatic stress disorderInduction chemotherapyIntensive chemotherapyUnmet psychological needsClinical trialsIllness trajectoryWeek 2Secondary analysisStress disorderOlder adultsPsychological distressLife disruptionChemotherapyWorse qualityAdultsAMLHigh anxietyAnxietyHospitalization
2021
Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival
Badar T, Litzow M, Shallis R, Bewersdorf J, Saliba A, De Camargo Correia G, Stahl M, Goldberg A, Atallah E, Foran J. Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival. Blood 2021, 138: 797. DOI: 10.1182/blood-2021-147639.Peer-Reviewed Original ResearchCR/CRiProportion of patientsStem cell transplantationComplex cytogeneticsVariant allele frequencyCPX-351Overall survivalAML patientsNovel therapiesTP53 mutationsCell transplantationUnivariate analysisAllogeneic hematopoietic stem cell transplantationMedian progression-free survivalAllogeneic stem cell transplantationHematopoietic stem cell transplantationAdvisory CommitteeAML induction therapyExtra-medullary diseaseHigh-risk AMLInduction/consolidationVenetoclax combination therapyVenetoclax-based regimensMedian overall survivalMulticenter observational study
2008
Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)
Grant S, Kolla S, Sirulnik L, Shapiro G, Supko J, Cooper B, Perkins E, Ramakrishnan V, Espinoza-Delgado I, Tombes M, Roberts J. Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2). Blood 2008, 112: 2986. DOI: 10.1182/blood.v112.11.2986.2986.Peer-Reviewed Original ResearchAcute leukemiaDose levelsStandard therapyI trialDay 1Grade 4 non-hematologic toxicityPoor-prognosis acute leukemiaDe novo acute leukemiaExcess blasts-2High-risk AMLNon-hematologic toxicitiesRemission induction failurePoor risk factorsImatinib-Refractory Chronic Myeloid LeukemiaPhase I trialPhase II evaluationAML/MDSCorrelative laboratory studiesNovo acute leukemiaChronic myeloid leukemiaHDAC inhibitor vorinostatCDK inhibitor flavopiridolAbsence of leukemiaPost-treatment effectsBolus schedule
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply